Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cell Therapy for Chronic Spinal Cord Injury (HBSCI02), Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Spinal Cord Injury (HBSCI04 & HBSCI05)

NCT04064957 is registered in ClinicalTrials.gov with Hope Biosciences Research Foundation as lead sponsor.

NCT NCT04064957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04064957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cell Therapy for Chronic Spinal Cord Injury (HBSCI02), Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Spinal Cord Injury (HBSCI04 & HBSCI05)
Lead sponsor
Hope Biosciences Research Foundation
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal cord injuries